COPD
Conditions
Brief summary
This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators
Interventions
DRUGTrelegy or Anoro
Both drugs delivered via Ellipta device and blinded package appearance
Sponsors
Mahidol University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients who have met the criteria for COPD GOLD B defined by an exacerbation not more than 1 time in the last year prior to the study enrollment. These patients will be recruited in sequential sequence. * Patients with COPD GOLD B are previously treated with either LAMA or LAMA/LABA or short-acting bronchodilators * Patients who are able to provide informed consent.
Exclusion criteria
* \- Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung, other malignancy, active heart diseases. * Receiving long-term treatment with immunosuppressive drugs and systemic corticosteroids * Being treated with triple therapy (ICS/LABA/LAMA) * Being in terminally ill conditions
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in lung volume | 4 weeks | TLC, RV, RV/TLC, IOS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Inflammatory cytokines | 4 weeks | FENO, hs-CRP, sputum cell counts and differential counts |
Countries
Thailand
Contacts
Primary Contactkittipong maneechotesuwan, MD, PhD.
Outcome results
None listed